MAPT and Alzheimer disease: As for CSF AD biomarkers, the high risk group had higher levels of CSF AD biomarkers level compared with the low (t-tau: P < 0.001; p-tau: P < 0.001; t-tau/Aβ42: P = 0.002) and intermedium (t-tau: P < 0.001; p-tau: P < 0.001; t-tau/Aβ42: P = 0.002) risk groups (Fig. 1C-E).